Guidelines for treatment and prevention of venous thromboembolism among patients with cancer

Thrombosis Research

Volumn 133, Issue SUPPL. 2, 2014, Pages

  Kuderer, Nicole M ^a   Lyman, Gary H ^a  

^a USA   (United States)

Author keywords

Anticoagulation; Cancer; Guidelines; Pulmonary embolism; Thrombosis; Venous thromboembolism

Indexed keywords

ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTIVITAMIN K; DALTEPARIN; DEXAMETHASONE; ENOXAPARIN; FONDAPARINUX; HEMOGLOBIN; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SEMULOPARIN; THALIDOMIDE;

ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; COMPRESSION STOCKING; HOSPITAL PATIENT; HUMAN; KIDNEY CANCER; LEUKOCYTE COUNT; LUNG CANCER; LYMPHOMA; MYELOMA; OUTPATIENT; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH CANCER; THROMBOCYTE COUNT; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; BLOOD; COMPLICATION; NEOPLASM; ONCOLOGY; STANDARDS;

HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; VENOUS THROMBOEMBOLISM;

EID: 84901455646     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(14)50021-7     Document Type: Article

References (100)

1. A. Alcalay, T. Wun, V. Khatri, H.K. Chew, D. Harvey, and H. Zhou et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival J Clin Oncol 24 2006 1112 1118 (Pubitemid 46638808)
2. H.K. Chew, T. Wun, D.J. Harvey, H. Zhou, and R.H. White Incidence of venous thromboembolism and the impact on survival in breast cancer patients J Clin Oncol 25 2007 70 76 (Pubitemid 350003053)
3. H.K. Chew, T. Wun, D. Harvey, H. Zhou, and R.H. White Incidence of venous thromboembolism and its effect on survival among patients with common cancers Arch Intern Med 166 2006 458 464
4. N.M. Kuderer, T.L. Ortel, and C.W. Francis Impact of venous thromboembolism and anticoagulation on cancer and cancer survival J Clin Oncol 27 2009 4902 4911
5. H.T. Sorensen, L. Mellemkjaer, J.H. Olsen, and J.A. Baron Prognosis of cancers associated with venous thromboembolism N Engl J Med 343 2000 1846 1850 (Pubitemid 32104130)
6. P. Prandoni, A.W. Lensing, A. Piccioli, E. Bernardi, P. Simioni, and B. Girolami et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 2002 3484 3488 (Pubitemid 35303914)
7. L.S. Elting, C.P. Escalante, C. Cooksley, E.B. Avritscher, D. Kurtin, and L. Hamblin et al. Outcomes and cost of deep venous thrombosis among patients with cancer Arch Intern Med 164 2004 1653 1661 (Pubitemid 39037944)
8. M.B. Streiff, P.L. Bockenstedt, S.R. Cataland, C. Chesney, C. Eby, and J. Fanikos et al. Venous thromboembolic disease J Natl Compr Canc Netw 11 2013 1402 1429
9. M. Mandala, A. Falanga, and F. Roila Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines Ann Oncol 22 Suppl 6 2011 vi85 92
10. S. Siragusa, U. Armani, M. Carpenedo, A. Falanga, F. Fulfaro, and D. Imberti et al. Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) (1) Thromb Res 129 2012 e171 e176
11. D. Farge, P. Debourdeau, M. Beckers, C. Baglin, R.M. Bauersachs, and B. Brenner et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer J Thromb Haemost 11 2013 56 70
12. G.H. Lyman, A.A. Khorana, A. Falanga, D. Clarke-Pearson, C. Flowers, and M. Jahanzeb et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer J Clin Oncol 25 2007 5490 5505 (Pubitemid 350232226)
13. N.M. Kuderer, A.A. Khorana, G.H. Lyman, and C.W. Francis A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications Cancer 110 2007 1149 1161 (Pubitemid 47312882)
14. G.H. Lyman, A.A. Khorana, N.M. Kuderer, A.Y. Lee, J.I. Arcelus, and E.P. Balaban et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 31 2013 2189 2204
15. J.A. Heit, M.D. Silverstein, D.N. Mohr, T.M. Petterson, W.M. O'Fallon, and L.J. Melton III. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study Arch Intern Med 160 2000 809 815 (Pubitemid 30165241)
16. A.A. Khorana, C.W. Francis, E. Culakova, and G.H. Lyman Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study Cancer 104 2005 2822 2829 (Pubitemid 41798294)
17. A.A. Khorana, C.W. Francis, E. Culakova, R.I. Fisher, N.M. Kuderer, and G.H. Lyman Thromboembolism in hospitalized neutropenic cancer patients J Clin Oncol 24 2006 484 490 (Pubitemid 46630468)
18. R.S. Komrokji, N.P. Uppal, A.A. Khorana, G.H. Lyman, K.L. Kaplan, and R.I. Fisher et al. Venous thromboembolism in patients with diffuse large B-cell lymphoma Leuk Lymphoma 47 2006 1029 1033
19. A. Falanga, and M. Marchetti Venous thromboembolism in the hematologic malignancies J Clin Oncol 27 2009 4848 4857
20. M. Cavo, E. Zamagni, C. Cellini, P. Tosi, D. Cangini, and M. Cini et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy Blood 100 2002 2272 2273 (Pubitemid 35001274)
21. F. Kabbinavar, H.I. Hurwitz, L. Fehrenbacher, N.J. Meropol, W.F. Novotny, and G. Lieberman et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 2003 60 65
22. B.C. Kuenen, M. Levi, J.C. Meijers, V.W. Van Hinsbergh, J. Berkhof, and A.K. Kakkar et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416 J Clin Oncol 21 2003 2192 2198 (Pubitemid 46606369)
23. F.A. Scappaticci, J.R. Skillings, S.N. Holden, H.P. Gerber, K. Miller, and F. Kabbinavar et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 2007 1232 1239 (Pubitemid 47299901)
24. S.R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis JAMA 300 2008 2277 2285
25. M. Zangari, L.M. Fink, F. Elice, F. Zhan, D.M. Adcock, and G.J. Tricot Thrombotic events in patients with cancer receiving antiangiogenesis agents J Clin Oncol 27 2009 4865 4873
26. H.I. Hurwitz, L.B. Saltz, E. Van Cutsem, J. Cassidy, J. Wiedemann, and F. Sirzen et al. Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of patients in randomized phase II and III studies J Clin Oncol 29 2011 1757 1764
27. J. Bohlius, J. Wilson, J. Seidenfeld, M. Piper, G. Schwarzer, and J. Sandercock et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients J Natl Cancer Inst 98 2006 708 714 (Pubitemid 43821788)
28. A.A. Khorana, C.W. Francis, N. Blumberg, E. Culakova, M.A. Refaai, and G.H. Lyman Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer Arch Intern Med 168 2008 2377 2381
29. A.A. Khorana, N.M. Kuderer, E. Culakova, G.H. Lyman, and C.W. Francis Development and validation of a predictive model for chemotherapy-associated thrombosis Blood 111 2008 4902 4907
30. A.A. Khorana, and G.C. Connolly Assessing risk of venous thromboembolism in the patient with cancer J Clin Oncol 27 2009 4839 4847
31. American Cancer Society Cancer facts and figures for African Americans 2011-2012 2011 American Cancer Society Atlanta
32. C. Ay, D. Dunkler, C. Marosi, A.L. Chiriac, R. Vormittag, and R. Simanek et al. Prediction of venous thromboembolism in cancer patients Blood 116 2010 5377 5382
33. A.A. Khorana, C. O'Connell, G. Agnelli, H.A. Liebman, and A.Y. Lee Subcommittee on H, et al. Incidental venous thromboembolism in oncology patients J Thromb Haemost 10 2012 2602 2604
34. George DJ, Agnelli G, Fisher W, AK K, Lassen MR, Mismetti P, et al. Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE- ONCO. Blood 2011;ASH Annual Meeting Program and Proceedings(206).
35. M. Verso, G. Agnelli, S. Barni, G. Gasparini, and R. LaBianca A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score Intern Emerg Med 7 2012 291 292
36. A.Y. Lee Anticoagulation in the treatment of established venous thromboembolism in patients with cancer J Clin Oncol 27 2009 4895 4901
37. G.H. Lyman Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer Cancer 115 2009 5637 5650
38. M.N. Levine New antithrombotic drugs: potential for use in oncology J Clin Oncol 27 2009 4912 4918
39. P.L. den Exter, J. Hooijer, O.M. Dekkers, and M.V. Huisman Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: A comparison with symptomatic patients J Clin Oncol 29 2011 2405 2409
40. C.L. O'Connell, W.D. Boswell, V. Duddalwar, A. Caton, L.S. Mark, and C. Vigen et al. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance J Clin Oncol 24 2006 4928 4932 (Pubitemid 46630922)
41. J.L. Ambrus, C.M. Ambrus, I.B. Mink, and J.W. Pickren Causes of death in cancer patients J Med 6 1975 61 64
42. S. Sallah, J.Y. Wan, and N.P. Nguyen Venous thrombosis in patients with solid tumors: determination of frequency and characteristics Thromb Haemost 87 2002 575 579 (Pubitemid 34302943)
43. P.D. Stein, A. Beemath, F.A. Meyers, E. Skaf, J. Sanchez, and R.E. Olson Incidence of venous thromboembolism in patients hospitalized with cancer Am J Med 119 2006 60 68 (Pubitemid 43117468)
44. N. Levitan, A. Dowlati, S.C. Remick, H.I. Tahsildar, L.D. Sivinski, and R. Beyth et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data Medicine (Baltimore) 78 1999 285 291 (Pubitemid 29439263)
45. A.T. Cohen, B.L. Davidson, A.S. Gallus, M.R. Lassen, M.H. Prins, and W. Tomkowski et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial BMJ 332 2006 325 329
46. A. Leizorovicz, A.T. Cohen, A.G. Turpie, C.G. Olsson, P.T. Vaitkus, and S.Z. Goldhaber Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients Circulation 110 2004 874 879 (Pubitemid 39096017)
47. M.M. Samama, A.T. Cohen, J.Y. Darmon, L. Desjardins, A. Eldor, and C. Janbon et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group N Engl J Med 341 1999 793 800 (Pubitemid 29420474)
48. C.W. Francis Prevention of venous thromboembolism in hospitalized patients with cancer J Clin Oncol 27 2009 4874 4880
49. R.D. Hull, S.M. Schellong, V.F. Tapson, M. Monreal, M.M. Samama, and P. Nicol et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: A randomized trial Ann Intern Med 153 2010 8 18
50. H. Riess, S. Haas, U. Tebbe, H.E. Gerlach, C. Abletshauser, and C. Sieder et al. A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study J Thromb Haemost 8 2010 1209 1215
51. S.M. Schellong, S. Haas, A. Greinacher, U. Schwanebeck, C. Sieder, and C. Abletshauser et al. An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN Expert Opin Pharmacother 11 2010 2953 2961
52. M. Carrier, A.A. Khorana, P. Moretto, G. Le Gal, R. Karp, and J.I. Zwicker Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer Am J Med 127 1 2014 82 86 e1
53. A.K. Kakkar, S. Haas, H. Wolf, and A. Encke Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy Thromb Haemost 94 2005 867 871 (Pubitemid 41489251)
54. A.K. Kakkar Prevention of venous thromboembolism in the cancer surgical patient J Clin Oncol 27 2009 4881 4884
55. D.L. Clarke-Pearson, I.S. Synan, R. Dodge, J.T. Soper, A. Berchuck, and R.E. Coleman A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery Am J Obstet Gynecol 168 1993 1146 1153 discussion 53-4
56. D.L. Clarke-Pearson, R.K. Dodge, I. Synan, R.C. McClelland, and G.L. Maxwell Venous thromboembolism prophylaxis: patients at high risk to fail intermittent pneumatic compression Obstet Gynecol 101 2003 157 163 (Pubitemid 36057102)
57. P. Roderick, G. Ferris, K. Wilson, H. Halls, D. Jackson, R. Collins, and C. Baigent Health Technol Assess 9 2005 1 78
58. V.V. Kakkar, S. Sagar, and M. Lewis Lancet 2 1975 674 676 [80]
59. D. Bergqvist, U.S. Burmark, P.A. Flordal, J. Frisell, T. Hallbook, and M. Hedberg et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients Br J Surg 82 1995 496 501
60. P. Wille-Jorgensen, M.S. Rasmussen, B.R. Andersen, and L. Borly Heparins and mechanical methods for thromboprophylaxis in colorectal surgery Cochrane Database Syst Rev 2003 CD001217
61. D. Bergqvist, G. Agnelli, A.T. Cohen, A. Eldor, P.E. Nilsson, and A. Le Moigne-Amrani et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer N Engl J Med 346 2002 975 980 (Pubitemid 34983247)
62. M.S. Rasmussen Does prolonged thromboprophylaxis improve outcome in patients undergoing surgery? Cancer Treat Rev 29 Suppl 2 2003 15 17 (Pubitemid 36758233)
63. W.H. Geerts, G.F. Pineo, J.A. Heit, D. Bergqvist, M.R. Lassen, and C.W. Colwell et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on [84] Antithrombotic and Thrombolytic Therapy Chest 126 3 Suppl 2004 338S 400S (Pubitemid 39302602)
64. A.K. Kakkar, G. Agnelli, W. Fisher, D. George, P. Mouret, and M.R. Lassen et al. The Ultra-Low-Molecular-Weight Heparin Semuloparin for Prevention of Venous Thromboembolism In Patients Undergoing Major Abdominal Surgery American Society of Hematology 2011
65. M. Sakon, T. Kobayashi, and T. Shimazui Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study Thromb Res 125 2010 e65 e70
66. G. Simonneau, S. Laporte, P. Mismetti, A. Derlon, K. Samii, and C.M. Samama et al. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer J Thromb Haemost 4 2006 1693 1700 (Pubitemid 44144795)
67. E.A. Akl, I. Terrenato, M. Barba, F. Sperati, P. Muti, and H.J. Schunemann Extended perioperative thromboprophylaxis in patients with cancer. A systematic review Thromb Haemost 100 2008 1176 1180
68. F.J. Bottaro, M.C. Elizondo, C. Doti, J.E. Bruetman, P.D. Perez Moreno, and E.O. Bullorsky et al. Efficacy of extended thrombo-prophylaxis in major abdominal surgery: what does the evidence show? A meta-analysis. Thromb Haemost 99 2008 1104 1111 (Pubitemid 351810493)
69. M.S. Borly, L.N. Joigensen, and P. Wille-Joigensen Prolonged thromboprophylaxis with Low Molecular Weight heparin for abdominal or pelvic surgery (Review) Cochrane Database Syst Rev 2009 CD004318
70. T. Wun, L. Law, D. Harvey, B. Sieracki, S.A. Scudder, and J.K. Ryu Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin Cancer 98 2003 1514 1520 (Pubitemid 37151508)
71. M.Q. Rosenzweig, C.M. Bender, J.P. Lucke, J.M. Yasko, and A.M. Brufsky The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events J Pain Symptom Manage 27 2004 185 190 (Pubitemid 38221077)
72. B. Barlogie, G. Tricot, E. Anaissie, J. Shaughnessy, E. Rasmussen, and F. Van Rhee et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma N Engl J Med 354 2006 1021 1030 (Pubitemid 43357806)
73. S.V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P.R. Greipp Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 24 2006 431 436 (Pubitemid 46630462)
74. J.A. Zonder, B.G.M. Durie, J. McCoy, J. Crowley, J.B. Zeldis, and L. Ghannam et al. High Incidence of Thrombotic Events Observed in Patients Receiving Lenalidomide (L) + Dexamethasone (D) (LD) as First-Line Therapy for Multiple Myeloma (MM) without Aspirin (ASA) Prophylaxis Blood 106 2005 3455
75. M. Zangari, E. Anaissie, B. Barlogie, A. Badros, R. Desikan, and A.V. Gopal et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy Blood 98 2001 1614 1615
76. M. Zangari, B. Barlogie, E. Anaissie, F. Saghafifar, P. Eddlemon, and J. Jacobson et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation Br J Haematol 126 2004 715 721 (Pubitemid 39221309)
77. C. Rus, M. Bazzan, A. Palumbo, S. Bringhen, and M. Boccadoro Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis J Thromb Haemost 2 2004 2063 2065 (Pubitemid 40192769)
78. S.V. Rajkumar Thalidomide therapy and deep venous thrombosis in multiple myeloma Mayo Clin Proc 80 2005 1549 1551 (Pubitemid 41747055)
79. B. Barlogie, S. Jagannath, K.R. Desikan, S. Mattox, D. Vesole, and D. Siegel et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 93 1999 55 65 (Pubitemid 29019388)
80. D. Weber, K. Rankin, M. Gavino, K. Delasalle, and R. Alexanian Thalidomide alone or with dexamethasone for previously untreated multiple myeloma J Clin Oncol 21 2003 16 19
81. M. Zangari, B. Barlogie, R. Thertulien, J. Jacobson, P. Eddleman, and L. Fink et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival Clin Lymphoma 4 2003 32 35 (Pubitemid 36826874)
82. G. Agnelli, G. Gussoni, C. Bianchini, M. Verso, M. Mandala, and L. Cavanna et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study Lancet Oncol 10 2009 943 949
83. A. Maraveyas, J. Waters, R. Roy, D. Fyfe, D. Propper, and F. Lofts et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer Eur J Cancer 48 2012 1283 1292
84. H. Riess, U. Pelzer, A. Hilbig, J. Stieler, B. Opitz, and T. Scholten et al. Rationale and design of PROSPECT-CONKO 004: A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy) BMC Cancer 8 2008 361
85. Riess H, Pelzer U, Opitz B, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy. Final Results of the CONKO-004 trial. American Society of Clinical Oncology (ASCO) Annual Meeting, June 2010. 2010.
86. G. Agnelli, D.J. George, A.K. Kakkar, W. Fisher, M.R. Lassen, and P. Mismetti et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer N Engl J Med 366 2012 601 609
87. Kuderer NM, Ortel TL, Khorana AA, et al. Low-molecular-weight heparin for venous thromboprophylaxis in ambulatory cancer patients: A systematic review meta-analysis of randomized controlled trials. American Society of Hematology (ASH) Annual Meeting, December 2009. 2009.
88. R. Castelli, F. Porro, and P. Tarsia The heparins and cancer: review of clinical trials and biological properties Vasc Med 9 2004 205 213 (Pubitemid 40124086)
89. R.H. Cosgrove, L.R. Zacharski, E. Racine, and J.C. Andersen Improved cancer mortality with low-molecular-weight heparin treatment: A review of the evidence Semin Thromb Hemost 28 2002 79 87 (Pubitemid 34194875)
90. S. Siragusa, B. Cosmi, F. Piovella, J. Hirsh, and J.S. Ginsberg Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis Am J Med 100 1996 269 277 (Pubitemid 26111623)
91. M.K. Gould, A.D. Dembitzer, R.L. Doyle, T.J. Hastie, and A.M. Garber Low-molecular- weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials Ann Intern Med 130 1999 800 809 (Pubitemid 29231148)
92. R.J. Hettiarachchi, S.M. Smorenburg, J. Ginsberg, M. Levine, M.H. Prins, and H.R. Buller Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread Thromb Haemost 82 1999 947 952
93. L.R. Dolovich, J.S. Ginsberg, J.D. Douketis, A.M. Holbrook, and G. Cheah A metaanalysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency Arch Intern Med 160 2000 181 188 (Pubitemid 30054337)
94. L.R. Zacharski, W.G. Henderson, F.R. Rickles, W.B. Forman, C.J. Cornell Jr., and R.J. Forcier et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75 Cancer 53 1984 2046 2052 (Pubitemid 14101772)
95. A.P. Chahinian, K.J. Propert, J.H. Ware, B. Zimmer, M.C. Perry, and V. Hirsh et al. A randomized trial of anticoagulation with warfar in and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B J Clin Oncol 7 1989 993 1002 (Pubitemid 19196521)
96. L.H. Maurer, J.E. Herndon 2nd, D.R. Hollis, J. Aisner, R.W. Carey, and A.T. Skarin et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: A Cancer and Leukemia Group B study J Clin Oncol 15 1997 3378 3387 (Pubitemid 27485858)
97. B. Lebeau, C. Chastang, J.M. Brechot, F. Capron, B. Dautzenberg, and C. Delaisements et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group Cancer 74 1994 38 45 (Pubitemid 24187607)
98. M. Altinbas, H.S. Coskun, O. Er, M. Ozkan, B. Eser, and A. Unal et al. A randomized clinical trial of combination chemotherapy with and without low- molecular-weight heparin in small cell lung cancer J Thromb Haemost 2 2004 1266 1271 (Pubitemid 40186120)
99. C.P. Klerk, S.M. Smorenburg, H.M. Otten, A.W. Lensing, M.H. Prins, and F. Piovella et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy J Clin Oncol 23 2005 2130 2135 (Pubitemid 46218704)
100. K. Sideras, P.L. Schaefer, S.H. Okuno, J.A. Sloan, L. Kutteh, and T.R. Fitch et al. Low- molecular-weight heparin in patients with advanced cancer: A phase 3 clinical trial Mayo Clin Proc 81 2006 758 767 (Pubitemid 43839491)